FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
As 2025 begins, key trends in aesthetic medicine focus on advancements such as preservation rhinoplasty, personalized body contouring, facial optimization for the digital age, enhanced recovery techniques, and preventative treatments designed to deliver natural results and improve patient outcomes.